Business Description
Li Kang Biomedical Co Ltd
ISIN : TW0006242001
Total Employee Number:
116Description
Li Kang Biomedical Co Ltd is a Taiwan based company engages in tourism factory businesses, telemarketing, as well as the manufacturing and sales of cosmetics and hygienic drinks.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 1.31 | |||||
Interest Coverage | 264.2 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.38 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.1 | |||||
3-Year EBITDA Growth Rate | -13.4 | |||||
3-Year EPS without NRI Growth Rate | -14.3 | |||||
3-Year Book Growth Rate | 10 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.81 | |||||
9-Day RSI | 46.74 | |||||
14-Day RSI | 43.01 | |||||
3-1 Month Momentum % | -4.56 | |||||
6-1 Month Momentum % | -6.03 | |||||
12-1 Month Momentum % | -13.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.5 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 1.13 | |||||
Days Inventory | 92.67 | |||||
Days Sales Outstanding | 5.96 | |||||
Days Payable | 36.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.56 | |||||
Dividend Payout Ratio | 0.76 | |||||
3-Year Dividend Growth Rate | 16.6 | |||||
Forward Dividend Yield % | 5.56 | |||||
5-Year Yield-on-Cost % | 7.36 | |||||
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | 0.32 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.59 | |||||
Operating Margin % | 16.68 | |||||
Net Margin % | 14.23 | |||||
EBITDA Margin % | 19.22 | |||||
FCF Margin % | -40.29 | |||||
OCF Margin % | 15.64 | |||||
ROE % | 9.81 | |||||
ROA % | 7.63 | |||||
ROIC % | 9.98 | |||||
3-Year ROIIC % | -5.62 | |||||
ROC (Joel Greenblatt) % | 17.34 | |||||
ROCE % | 11.34 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.67 | |||||
PE Ratio without NRI | 13.67 | |||||
Shiller PE Ratio | 10.1 | |||||
Price-to-Owner-Earnings | 112.89 | |||||
PEG Ratio | 7.19 | |||||
PS Ratio | 1.95 | |||||
PB Ratio | 1.32 | |||||
Price-to-Tangible-Book | 1.31 | |||||
Price-to-Operating-Cash-Flow | 12.5 | |||||
EV-to-EBIT | 10.55 | |||||
EV-to-EBITDA | 9.74 | |||||
EV-to-Revenue | 1.87 | |||||
EV-to-FCF | -4.63 | |||||
Price-to-GF-Value | 0.92 | |||||
Price-to-Projected-FCF | 1.12 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
Price-to-Graham-Number | 0.89 | |||||
| Price-to-Net-Current-Asset-Value | 36.68 | |||||
Earnings Yield (Greenblatt) % | 9.49 | |||||
FCF Yield % | -20.76 | |||||
Forward Rate of Return (Yacktman) % | 4.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Li Kang Biomedical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 589.209 | ||
| EPS (TTM) (NT$) | 2.63 | ||
| Beta | 0.4601 | ||
| 3-Year Sharpe Ratio | -1.64 | ||
| 3-Year Sortino Ratio | -1.67 | ||
| Volatility % | 6.26 | ||
| 14-Day RSI | 43.01 | ||
| 14-Day ATR (NT$) | 0.385299 | ||
| 20-Day SMA (NT$) | 35.9625 | ||
| 12-1 Month Momentum % | -13.05 | ||
| 52-Week Range (NT$) | 35 - 43.7 | ||
| Shares Outstanding (Mil) | 31.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Li Kang Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Li Kang Biomedical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 2.000000 Cash Dividend | 2026-06-16 | 38.15 (-0.13%) | ||
| TWD 2.000000 Cash Dividend | 2025-06-16 | 43.10 (+0.35%) | ||
| 1.15:1 Stock Split | 2023-06-30 | 66.67 (+0.38%) | ||
| 1.05:1 Stock Split | 2022-07-04 | 39.48 (-3.33%) | ||
| 1.11:1 Stock Split | 2016-08-31 | 36.07 (+0.00%) | ||
| 0.267761:1 Stock Split | 2014-03-28 | 19.13 (+0.00%) | ||
| 0.60581:1 Stock Split | 2009-04-08 | 10.54 (+6.76%) |
Show
Entries
Li Kang Biomedical Co Ltd Frequently Asked Questions
What is Li Kang Biomedical Co Ltd(ROCO:6242)'s stock price today?
The current price of ROCO:6242 is NT$35.95. The 52 week high of ROCO:6242 is NT$43.70 and 52 week low is NT$35.00.
When is next earnings date of Li Kang Biomedical Co Ltd(ROCO:6242)?
The next earnings date of Li Kang Biomedical Co Ltd(ROCO:6242) is .
Does Li Kang Biomedical Co Ltd(ROCO:6242) pay dividends? If so, how much?
The Dividend Yield %  of Li Kang Biomedical Co Ltd(ROCO:6242) is 5.56% (As of Today), Highest Dividend Payout Ratio of Li Kang Biomedical Co Ltd(ROCO:6242) was 1.21. The lowest was 0.02. And the median was 0.69. The  Forward Dividend Yield % of Li Kang Biomedical Co Ltd(ROCO:6242) is 5.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Li Kang Biomedical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers